The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: ) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown. METHODS: mutation-positive NSCLC in a 1:1 ratio to receive either osimertinib (80 mg once daily) or placebo for 3 years. The primary end point was disease-free survival among patients with stage II to IIIA disease (according to investigator assessment). The secondary end points included disease-free survival in the overall population of patients with stage IB to IIIA disease, overall survival, and safety. RESULTS: A total of 682 patients underwent randomization (339 to the osimertinib group and 343 to the placebo group). At 24 months, 90% of the patients with stage II to IIIA disease in the osimertinib group (95% confidence interval [CI], 84 to 93) and 44% of those in the placebo group (95% CI, 37 to 51) were alive and disease-free (overall hazard ratio for disease recurrence or death, 0.17; 99.06% CI, 0.11 to 0.26; P<0.001). In the overall population, 89% of the patients in the osimertinib group (95% CI, 85 to 92) and 52% of those in the placebo group (95% CI, 46 to 58) were alive and disease-free at 24 months (overall hazard ratio for disease recurrence or death, 0.20; 99.12% CI, 0.14 to 0.30; P<0.001). At 24 months, 98% of the patients in the osimertinib group (95% CI, 95 to 99) and 85% of those in the placebo group (95% CI, 80 to 89) were alive and did not have central nervous system disease (overall hazard ratio for disease recurrence or death, 0.18; 95% CI, 0.10 to 0.33). Overall survival data were immature; 29 patients died (9 in the osimertinib group and 20 in the placebo group). No new safety concerns were noted. CONCLUSIONS: mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationOsimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationEpidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Self-citationLung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Self-citationPlanchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Douillard, J.-Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzáles-Larriba, J. L., Grodzki, T., Pereira, J. R., Le Groumellec, A., Lorusso, V., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70804-x · Cited by 1,573
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3118 · Cited by 811
Self-citationBallard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718
Testing for Qualitative Interactions between Treatment Effects and Patient Subsets
Gail, M., & Simon, R. (1985) · Biometrics · doi:10.2307/2530862 · Cited by 651
Hanna, N., Johnson, D., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Giaccone, G., Hesketh, P. J., Jaiyesimi, I., Leighl, N. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.6065 · Cited by 643
Zhong, W.-Z., Wang, Q., Mao, W.-M., Xu, S.-T., Wu, L., Shen, Y., Liu, Y.-Y., Chen, C., Cheng, Y., Xu, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30729-5 · Cited by 529
Self-citationWu, Y.-L., Ahn, M.-J., Garassino, M. C., Han, J.-Y., Katakami, N., Kim, H. R., Hodge, R., Kaur, P., Brown, A. P., Ghiorghiu, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9363 · Cited by 517
Self-citationVansteenkiste, J. F., Cho, B. C., Vanakesa, T., De Pas, T., Zielinski, M., Kim, M. S., Jassem, J., Yoshimura, M., Dahabreh, J., Nakayama, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00099-1 · Cited by 511
Self-citationKelly, K., Altorki, N. K., Eberhardt, W. E. E., O'Brien, M. E. R., Spigel, D. R., Crinò, L., Tsai, C.-M., Kim, J.-H., Cho, E. K., Hoffman, P. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.8918 · Cited by 480
Self-citationSholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000516 · Cited by 430
Kris, M. G., Gaspar, L. E., Chaft, J. E., Kennedy, E. B., Azzoli, C. G., Ellis, P. M., Lin, S. H., Pass, H. I., Seth, R., Shepherd, F. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.4401 · Cited by 368
Self-citationPeters, S., Bexelius, C., Munk, V., & Leighl, N. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.009 · Cited by 295
Wu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D. S. W., Yang, J. C.-H., Azrif, M., Mitsudomi, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 291
Self-citationYue, D., Xu, S., Wang, Q., Li, X., Shen, Y., Zhao, H., Chen, C., Mao, W., Liu, W., Liu, J., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30277-7 · Cited by 288
Wang, Z., Cheng, Y., An, T., Gao, H., Wang, K., Zhou, Q., Hu, Y., Song, Y., Ding, C., Peng, F., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30264-9 · Cited by 217
Self-citationPennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Jänne, P. A., Govindan, R., Evans, T. L., Costa, D. B., Wakelee, H. A., Heist, R. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00131 · Cited by 210
Preoperative Evaluation of Patients Undergoing Lung Resection Surgerya
Datta, D., & Lahiri, B. (2003) · Chest · doi:10.1378/chest.123.6.2096 · Cited by 202
Lung Cancer Biomarkers: Present Status and Future Developments
Cagle, P. T., Allen, T. C., & Olsen, R. J. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0319-cr · Cited by 162
Sequential Analysis of the Proportional Hazards Model
Sellke, T., & Siegmund, D. (1983) · Biometrika · doi:10.1093/biomet/70.2.315 · Cited by 155
Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?
Chevalier, T. L. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq376 · Cited by 128
Kenmotsu, H., Yamamoto, N., Yamanaka, T., Yoshiya, K., Takahashi, T., Ueno, T., Goto, K., Daga, H., Ikeda, N., Sugio, K., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02674 · Cited by 112
Self-citationWu, Y.-L. L. C., Herbst, R. S., Mann, H., Rukazenkov, Y., Marotti, M., & Tsuboi, M. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.004 · Cited by 111
Self-citationLi, N., Ou, W., Xiong, Y., Sun, H.-B., Zhang, L., Fang, Q., Zhang, S.-L., Wang, B.-X., & Wang, S. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3586-9 · Cited by 106
Xu, L., Xi, J., Zhong, W., Mao, W., Wu, L., Shen, Y., Liu, Y., Chen, C., Cheng, Y., Xu, L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.020 · Cited by 71
Self-citationIntratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator
Oh, B. Y., Shin, H., Yun, J. W., Kim, K., Kim, J.-H., Bae, J. S., Cho, Y. B., Lee, W. Y., Yun, S. H., Park, Y. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41098-0 · Cited by 61
A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer
Cheng, H., Li, X., Wang, X., Chen, Z.-W., Wang, R., Zhong, H., Wu, T.-C., & Cao, Q. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.002 · Cited by 59
Huang, Q., Li, J., Sun, Y., Wang, R., Cheng, X., & Chen, H. (2015) · CHEST Journal · doi:10.1016/j.chest.2015.12.017 · Cited by 52
A comparison of two simple hazard ratio estimators based on the logrank test
Sato, T. S., & Berry, G. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110614 · Cited by 44
Chang, W.-Y., Wu, Y., Su, P., Yang, S., Lin, C., & Su, W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192161 · Cited by 43
Self-citationCHOUAID, C., Danson, S. J., Andreas, S., Siakpere, O., Benjamin, L., Ehneß, R., Dramard-Goasdoue, M.-H., Barth, J., Hoffmann, H., Potter, V. A., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.042 · Cited by 43
Buck, P. O., Saverno, K. R., Miller, P. J., Arondekar, B. V., & Walker, M. S. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.010 · Cited by 31
Shi, P., Zhang, S., Zhu, L., Qian, G., Ren, H., Ramalingam, S. S., Chen, M., & Sun, S. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.02.006 · Cited by 30
Colclough, N., Ballard, P. G., Barton, P., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32664-8 · Cited by 24
Stone, A. M. (2009) · Pharmaceutical Statistics · doi:10.1002/pst.386 · Cited by 2
Cited by
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M. S., Beasley, M. B., Borczuk, A. C., Brambilla, E., Cooper, W. A., Dacic, S., Jain, D., Kerr, K. M., Lantuejoul, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,554
Felip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,486
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,093
Self-citation
Metadata
- Authors
- Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., Vu, H.-V., Lu, S., Lee, K.-Y., Akewanlop, C., Yu, C.-J., de Marinis, F., Bonanno, L., Domine, M., Shepherd, F. A., Zeng, L., Hodge, R., Atasoy, A., Rukazenkov, Y., & Herbst, R. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-29
- Volume
- 383
- Issue
- 18
- Pages
- 1711-1723
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3087210493
- Cited by
- 1,798
- References
- 47
- FWCI
- 130.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.